ANI PHARMACEUTICALS, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ANI PHARMACEUTICALS, INC (ANIP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.51M, a 19.88% increase year-over-year.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.19M, a 14.92% increase year-over-year.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $9.77M, a 38.34% increase year-over-year.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $9.69M, a 29.49% increase year-over-year.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.93M, a 29.26% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $29.34M, a 42.09% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $20.65M, a 41.46% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.60M, a 39.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.51M 10-Q · filed 2026-08-07 | $21.70M derived: sum of 2 quarters · filed 2026-08-07 | $31.47M derived: sum of 3 quarters · filed 2026-08-07 | $41.16M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $10.19M 10-Q · filed 2026-05-08 | $19.96M derived: sum of 2 quarters · filed 2026-05-08 | $29.65M derived: sum of 3 quarters · filed 2026-05-08 | $39.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $19.46M derived: sum of 2 quarters · filed 2026-02-27 | $29.06M derived: sum of 3 quarters · filed 2026-08-07 | $37.93M 10-K · filed 2026-02-27 |
| 2025-09-30 | $9.69M 10-Q · filed 2025-11-07 | $19.29M derived: sum of 2 quarters · filed 2026-08-07 | $28.16M 10-Q · filed 2025-11-07 | $35.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $9.60M 10-Q · filed 2026-08-07 | $18.47M 10-Q · filed 2026-08-07 | $25.53M derived: sum of 3 quarters · filed 2026-08-07 | $33.02M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $8.87M 10-Q · filed 2026-05-08 | $15.93M derived: sum of 2 quarters · filed 2026-05-08 | $23.41M derived: sum of 3 quarters · filed 2026-05-08 | $31.28M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.54M derived: sum of 2 quarters · filed 2026-02-27 | $22.41M derived: sum of 3 quarters · filed 2026-02-27 | $29.34M 10-K · filed 2026-02-27 |
| 2024-09-30 | $7.48M 10-Q · filed 2025-11-07 | $15.35M derived: sum of 2 quarters · filed 2025-11-07 | $22.28M 10-Q · filed 2025-11-07 | $27.90M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $7.86M 10-Q · filed 2025-08-08 | $14.80M 10-Q · filed 2025-08-08 | $20.42M derived: sum of 3 quarters · filed 2026-02-27 | $25.86M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $6.93M 10-Q · filed 2025-05-09 | $12.55M derived: sum of 2 quarters · filed 2026-02-27 | $18.00M derived: sum of 3 quarters · filed 2026-02-27 | $23.25M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.06M derived: sum of 2 quarters · filed 2026-02-27 | $16.31M derived: sum of 3 quarters · filed 2026-02-27 | $20.65M 10-K · filed 2026-02-27 |
| 2023-09-30 | $5.44M 10-Q · filed 2024-11-08 | $10.69M derived: sum of 2 quarters · filed 2024-11-08 | $15.03M 10-Q · filed 2024-11-08 | $18.77M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $5.25M 10-Q · filed 2024-08-06 | $9.59M 10-Q · filed 2024-08-06 | $13.32M derived: sum of 3 quarters · filed 2025-02-28 | $17.19M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $4.34M 10-Q · filed 2024-05-10 | $8.07M derived: sum of 2 quarters · filed 2025-02-28 | $11.95M derived: sum of 3 quarters · filed 2025-02-28 | $15.70M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $7.61M derived: sum of 2 quarters · filed 2025-02-28 | $11.36M derived: sum of 3 quarters · filed 2025-02-28 | $14.60M 10-K · filed 2025-02-28 |
| 2022-09-30 | $3.87M 10-Q · filed 2023-11-08 | $7.63M derived: sum of 2 quarters · filed 2023-11-08 | $10.86M 10-Q · filed 2023-11-08 | $13.83M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.76M 10-Q · filed 2023-08-09 | $6.99M 10-Q · filed 2023-08-09 | $9.96M derived: sum of 3 quarters · filed 2024-02-29 | $12.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.24M 10-Q · filed 2023-05-08 | $6.21M derived: sum of 2 quarters · filed 2024-02-29 | $9.01M derived: sum of 3 quarters · filed 2024-02-29 | $11.86M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.78M derived: sum of 2 quarters · filed 2024-02-29 | $8.62M derived: sum of 3 quarters · filed 2024-02-29 | $10.49M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-09 | $5.65M derived: sum of 2 quarters · filed 2022-11-09 | $7.52M 10-Q · filed 2022-11-09 | $9.91M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $2.84M 10-Q · filed 2022-08-08 | $4.71M 10-Q · filed 2022-08-08 | $7.11M derived: sum of 3 quarters · filed 2023-03-09 | $9.49M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-10 | $4.26M derived: sum of 2 quarters · filed 2023-03-09 | $6.64M derived: sum of 3 quarters · filed 2023-03-09 | $12.38M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.78M derived: sum of 2 quarters · filed 2023-03-09 | $10.51M derived: sum of 3 quarters · filed 2023-03-09 | $12.94M 10-K · filed 2023-03-09 |
| 2020-09-30 | $2.38M 10-Q · filed 2021-11-01 | $8.12M derived: sum of 2 quarters · filed 2021-11-01 | $10.54M 10-Q · filed 2021-11-01 | $12.99M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $5.74M 10-Q · filed 2021-08-06 | $8.16M 10-Q · filed 2021-08-06 | $10.60M derived: sum of 3 quarters · filed 2022-03-15 | $13.07M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $2.42M 10-Q · filed 2021-05-07 | $4.87M derived: sum of 2 quarters · filed 2022-03-15 | $7.34M derived: sum of 3 quarters · filed 2022-03-15 | $9.93M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.91M derived: sum of 2 quarters · filed 2022-03-15 | $7.51M derived: sum of 3 quarters · filed 2022-03-15 | $9.22M 10-K · filed 2022-03-15 |
| 2019-09-30 | $2.47M 10-Q · filed 2020-11-05 | $5.06M derived: sum of 2 quarters · filed 2020-11-05 | $6.77M 10-Q · filed 2020-11-05 | $8.60M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $2.59M 10-Q · filed 2020-08-06 | $4.30M 10-Q · filed 2020-08-06 | $6.13M derived: sum of 3 quarters · filed 2021-03-11 | $7.92M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $1.71M 10-Q · filed 2020-05-07 | $3.54M derived: sum of 2 quarters · filed 2021-03-11 | $5.33M derived: sum of 3 quarters · filed 2021-03-11 | $7.12M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $3.62M derived: sum of 2 quarters · filed 2021-03-11 | $5.41M derived: sum of 3 quarters · filed 2021-03-11 | $6.78M 10-K · filed 2021-03-11 |
| 2018-09-30 | $1.79M 10-Q · filed 2019-11-06 | $3.58M derived: sum of 2 quarters · filed 2019-11-06 | $4.95M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $1.78M 10-Q · filed 2019-08-07 | $3.16M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $1.38M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $6.09M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $6.07M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $3.86M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $3.42M 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $36.00K 10-K · filed 2016-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |